Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC

NCT07465276 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

32

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinoma (HNSCC)
Squamous Cell Carcinoma of the Head and Neck

Interventions

DRUG: Ficerafusp alfa
DRUG: Pembrolizumab

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]